Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus-encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells

Blood

Volumn 111, Issue 1, 2008, Pages 292-301

  Flavell, Joanne R ^a   Baumforth, Karl R N ^a   Wood, Victoria H J ^a   Davies, Gillian L ^a   Wei, Wenbin ^a   Reynolds, Gary M ^a   Morgan, Susan ^a   Boyce, Andrew ^a   Kelly, Gemma L ^a   Young, Lawrence S ^a   Murray, Paul G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN EBNA1; PROTEIN TYROSINE PHOSPHATASE RECEPTOR KAPPA; RECEPTOR; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GENETIC TRANSCRIPTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; TUMOR SUPPRESSOR GENE;

EID: 38049105629     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-11-059881     Document Type: Article

References (41)

1. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 2003;3:801-812.
2. Rawlins DR, Milman G, Hayward SD, Hayward GS. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell. 1985;42:859-868.
3. Lee MA, Diamond ME, Yates JL. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol. 1999;73:2974-2982.
4. Kennedy G, Komano J, Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci U S A. 2003;100:14269-14274.
5. Kube D, Vockerodt M, Weber O, et al. Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. J Virol. 1999;73:1630-1636.
6. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 1996;15:3117-3126.
7. Kang MS, Lu H, Yasui T, Sharpe A, et al. Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc Natl Acad Sci U S A. 2005;102:820-825.
8. Baumforth KR, Flavell JR, Reynolds GM, et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin's lymphoma cells. Blood. 2005;106:2138-2146.
9. Kamesaki H, Fukuhara S, Tatsumi E, et al. Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood. 1986;68:285-292.
10. Diehl V, Kirchner HH, Burrichter H, et al. Characteristics of Hodgkin's disease-derived cell lines. Cancer Treatment Reports. 1982;66:615-632.
11. Shimizu N, Yoshiyama H, Takada K. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J Virol. 1996;70:7260-7263.
12. Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. Transforming growth factor β (TGF-β)-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-β function. Mol Cell Biol. 2005;25:4703-4715.
13. Paterson Institute for Cancer Research. Target preparation for Affymetrix Genechip System. Available at: http://bioinf.picr.man.ac.uk/mbcf/downloads/ GeneChip Target Prep Protocol-CR-UK v2.pdf. Accessed August 23, 2007.
14. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high-density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185-193.
15. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.
16. Storey JD, Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol. 2003;224:149-157.
17. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.
18. Dohr O, Abel J. Transforming growth factor-beta1 coregulates mRNA expression of aryl hydrocarbon receptor and cell-cycle-regulating genes in human cancer cell lines. Biochem Biophys Res Commun. 1997;2411:86-91.
19. Siegel PM, Shu W, Massague J. Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression. J Biol Chem. 2003;278:35444-35450.
20. Kehlen A, Englert N, Seifert A, et al. Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer. 2004;109:833-8.
21. Chao CC, Hu S, Tsang M, et al. Effects of transforming growth factor-beta on murine astrocyte glutamine synthetase activity: implications in neuronal injury. J Clin Invest. 1992;90:1786-1793.
22. Suomela S, Cao L, Bowcock A, Saarialho-Kere U. Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J Invest Dermatol. 2004;122:717-721.
23. Whang-Peng J, Knutsen T, Jaffe ES, et al. Sequential analysis of 43 patients with non-Hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies. Blood. 1995;85:203-216.
24. Nakamura M, Kishi M, Sakaki T, et al. Novel tumor suppressor loci on 6q22-33 in primary central nervous system lymphomas. Cancer Res. 2003;63:737-741.
25. Kim YS, Kang HY, Kim JY, et al. Identification of target proteins of N-acetylglucosaminyl transferase V in human colon cancer and implications of protein tyrosine phosphatase kappa in enhanced cancer cell migration. Proteomics. 2006;6:1187-1191.
26. Yang Y, Gil M, Byun SM, Choi I, Pyun KH, Ha H. Transforming growth factor-β1 inhibits keratinocyte proliferation by upregulation of a receptortype tyrosine phosphatase ∼R-PTP-κ gene expression. Biochem Biophys Res Commun. 1996;228:807-812.
27. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577-584.
28. Hata A, Lo RS, Wotton D, Lagna G, Massague J. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature. 1997;388:82-87.
29. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature. 1999;400:687-693.
30. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci U S A. 2001;98:974-979.
31. Pray TR, Parlati F, Huang J, et al. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist Updat. 2002;5:249-258.
32. Seo SR, Lallemand F, Ferrand N, et al. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J. 2004;23:3780-3792.
33. Kuratomi G, Komuro A, Goto K, et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J. 2005;386:461-470.
34. Wood VH, O'Neil JD, Wei W, Stewart SE, Dawson CW, Young LS. Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. Oncogene. 2007;26:4135-4147.
35. Sap J, Jiang Y-P, Friedlander D, Grumet M, Schlessinger J. Receptor tyrosine phosphatase R-PTP-κ mediates homophilic binding. Mol Cell Biol. 1994;14:1-9.
36. Fuchs M, Muller T, Lerch MM, Ullrich A. Association of human protein-tyrosine phosphatase κ with members of the armadillo family. J Biol Chem. 1996;271:16712-16719.
37. Xu Y, Tan LJ, Grachtchouk V, Voorhees JJ, Fisher GJ. Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. J Biol Chem. 2005;280:42694-42700.
38. Kuppers R, Schmitz R, Distler V, Renne C, Brauninger A, Hansmann ML. Pathogenesis of Hodgkin's lymphoma. Eur J Haematol Suppl. 2005;66:26-33.
39. Renne C, Willenbrock K, Kuppers R, Hansmann ML, Brauninger A. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood. 2005;105:4051-4059.
40. Prokova V, Mosialos G, Kardassis D. Inhibition of transforming growth factor β signalling and smad-dependent activation of transcription by the latent membrane protein 1 of Epstein-Barr virus. J Biol Chem. 2002;277:9342-9350.
41. Mori N, Morishita M, Tsukazaki T, Yamamoto N. Repression of Smad- dependent transforming growth factor-β signalling by Epstein-Barr virus latent membrane protein 1 through nuclear factor-κB. Int J Cancer. 2003;105:661-668.